18F-FDG PET/CT in hepatocellular carcinoma: Detection of bone metastasis and prediction of prognosis

Nuclear Medicine Communications

Volumn 36, Issue 3, 2015, Pages 226-233

  Seo, Hyo Jung ^a,e   Kim, Gun Min ^b   Kim, Joo Hoon ^b   Kang, Won Jun ^c   Choi, Hye Jin ^b,d  

^a Korea University College of Medicine   (South Korea)

^b Division of Oncology   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

bone metastasis; hepatocellular carcinoma; positron emission tomography; prognosis

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD PUGH SCORE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; HUMAN; LIVER CELL CARCINOMA; LUMBAR SPINE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PET-CT SCANNER; PREDICTION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL TIME; UNIVARIATE ANALYSIS; BONE; BONE NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; LIVER TUMOR; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOGRAPHY; SCINTISCANNING; SECONDARY; SENSITIVITY AND SPECIFICITY; SURVIVAL;

ADULT; AGED; BONE AND BONES; BONE NEOPLASMS; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84922404768     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000246     Document Type: Article

References (29)

1. Mochizuki T, Tsuda T, Sugawara Y, Tanaka H, Kikuchi T, Miyagawa M, et al. Tc-99m PMT hepatobiliary scintigraphy in the differential diagnosis of extrahepatic metastases and hepatocellular carcinoma. Clin Nucl Med 2000; 25:991-995
2. Fukutomi M, Yokota M, Chuman H, Harada H, Zaitsu Y, Funakoshi A, et al. Increased incidence of bone metastases in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2001; 13:1083-1088
3. Natsuizaka M, Omura T, Akaike T, Kuwata Y, Yamazaki K, Sato T, et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 2005; 20:1781-1787
4. Sugiyama M, Sakahara H, Torizuka T, Kanno T, Nakamura F, Futatsubashi M, Nakamura S. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004; 39:961-968
5. Kuhlman JE, Fishman EK, Leichner PK, Magid D, Order SE, Siegelman SS. Skeletal metastases from hepatoma: frequency, distribution, and radiographic features. Radiology 1986; 160:175-178
6. Chen CY, Hsueh YT, Lan TY, Lin WH, Wu K, Yang RS. Pelvic skeletal metastasis of hepatocellular carcinoma with sarcomatous change: a case report. Diagn Pathol 2010; 5:33
7. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol 2004; 22:2942-2953
8. Lee KH, Park JM, Yoon JK, Koh KC, Paik SW, Kim BT. Bone scintigraphy of skeletal metastasis in hepatoma patients treated by TAE. Hepatogastroenterology 2003; 50:1983-1986
9. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med 2005; 46:1356-1367
10. Chen YK, Hsieh DS, Liao CS, Bai CH, Su CT, Shen YY, et al. Utility of FDGPET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. Anticancer Res 2005; 25 (6C):4719-4725
11. Kim YK, Lee KW, Cho SY, Han SS, Kim SH, Kim SK, Park SJ. Usefulness of 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Liver Transpl 2010; 16:767-772
12. Kawaoka T, Aikata H, Takaki S, Uka K, Azakami T, Saneto H, et al. FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma. Hepatol Res 2009; 39:134-142
13. Higashi T, Hatano E, Ikai I, Nishii R, Nakamoto Y, Ishizu K, et al. FDG PETas a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2010; 37:468-482
14. Kim BK, Kang WJ, Kim JK, Seong J, Park JY, Kim do Y, et al. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally adVanced hepatocellular carcinoma. Cancer 2011; 117:4779-4787
15. Lee JW, Paeng JC, Kang KW, Kwon HW, Suh KS, Chung JK, et al. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 2009; 50:682-687
16. Liu N, Ma L, Zhou W, Pang Q, Hu M, Shi F, et al. Bone metastasis in patients with non-small cell lung cancer: the diagnostic role of F-18 FDG PET/CT. Eur J Radiol 2010; 74:231-235
17. Peterson JJ, Kransdorf MJ, OConnor MI. Diagnosis of occult bone metastases: positron emission tomography. Clin Orthop Relat Res 2003; Suppl:S120-S128
18. Cook GJ, Fogelman I. The role of positron emission tomography in the management of bone metastases. Cancer 2000; 88 (Suppl):2927-2933
19. Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003; 44:1200-1209
20. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology 2006; 238:405-422
21. PehliVan B, Topkan E, Onal C, Nursal GN, Yuksel O, Dolek Y, et al. Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma. Radiat Oncol 2009; 4:35
22. He J, Zeng ZC, Tang ZY, Fan J, Zhou J, Zeng MS, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer 2009; 115:2710-2720
23. Kim SU, Kim do Y, Park JY, Ahn SH, Nah HJ, Chon CY, Han KH. Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. J Cancer Res Clin Oncol 2008; 134:1377-1384
24. Iguchi H, Yokota M, Fukutomi M, Uchimura K, Yonemasu H, Hachitanda Y, et al. A possible role of VEGF in osteolytic bone metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 2002; 21:309-313
25. Machtay M, Natwa M, Andrel J, Hyslop T, Anne PR, Lavarino J, et al. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 2009; 31: 195-201
26. Borst GR, Belderbos JS, Boellaard R, Comans EF, De Jaeger K, Lammertsma AA, Lebesque JV. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 2005; 41:1533-1541
27. Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002; 43: 39-45
28. Yen RF, Chen CY, Cheng MF, Wu YW, Shiau YC, Wu K, et al. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Nucl Med Commun 2010; 31:637-645
29. Utsunomiya D, Shiraishi S, Imuta M, Tomiguchi S, Kawanaka K, Morishita S, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology 2006; 238: 264-271